Kymera Therapeutics (KYMR) announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The presentations include new data on its preclinical biomarker-based approach for KT-253, its MDM2 degrader. New data highlights the Company’s research efforts to identify patient populations sensitive to the KT-253 degrader mechanism and define biomarkers associated with an acute apoptotic response in tumors. Using an innovative machine learning framework to develop a predictive signature, the results identified tumor types sensitive to KT-253 that are consistent with preclinical and early clinical findings, including acute myeloid leukemia, neuroendocrine tumors, and subsets of solid tumors with or without neuroendocrine features
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics announces FDA clearance of IND application for KT-621
- Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
- Kymera Therapeutics presents data for KT-621 at EADV Congress
- Kymera assumed with Outperform from Market Perform at Leerink
- Boeing’s Starliner to return without astronauts: Morning Buzz